Academic Journals Database
Disseminating quality controlled scientific knowledge

Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome

Author(s): Daniele Porru | Enrica Bucchioni | Marcello Macchi | Fabio Leva | Alberto Parmigiani | Davide Barletta | Dimitrios Choussos | Barbara Gardella | Maria Diletta Daccò | Rossella Elena Nappi | Massimo Allegri | Carlo Maria Bianchi | Arsenio Spinillo | Bruno Rovereto

Journal: Urogynaecologia International Journal
ISSN 1121-3086

Volume: 26;
Issue: 1;
Start page: e8;
Date: 2012;
Original page

Keywords: anti-IgE treatment | interstitial cystitis/ bladder pain syndrome | omalizumab.

The aim of this study was to evaluate the efficacy of omalizumab in the treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS), evaluated by visual analogue score for pain and urgency- frequency, O’Leary-Sant IC symptom and problem index questionnaire, Pain Urgency Frequency questionnaire and Patient Global Assessment questionnaire. Four female patients with a diagnosis of IC/BPS were included in the study, with an age between 20 and 39 years. In the first patient the subjective final evaluation was of a marked improvement. The second patient had a moderate improvement of the subjective final evaluation. The third patient considered her overall clinical situation to have slightly improved after treatment. One 32-year-old patient, with multiple allergies, discontinued treatment after 3 months and could not complete the study due to side effects. Omalizumab was subcutaneously administered to patients with IC/PBS; it induced both a subjective and objective improvement of symptoms in 2 patients enrolled in the study.

Tango Rapperswil
Tango Rapperswil

     Affiliate Program